S265: Maternal and Perinatal Outcomes of Sickle Cell Disease in Pregnancy: A Nationwide Study in France.

Abstract

Sickle cell disease (SCD) is an inherited disease affecting the ß-chain of hemoglobin. With over 300,000 newborns per year, it is the world's most common hemoglobinopathy. Improved care for people with SCD has led to higher survival rates, which explains the increasing number of women with SCD who reach childbearing age. Pregnancy in women with SCD has been linked to a high risk of severe maternal and perinatal complications. In the largest and most recent meta-analysis of studies from both low-and high-income countries (encompassing 26,349 pregnant women with SCD), pregnancy was associated with an elevated risk of maternal mortality (relative risk (RR) [95% confidence interval (CI)] = 5. 98 [1.94-18.44]), preeclampsia (2.43 [1.75-3.39]), stillbirth (3.94 [2.60-5.96]), preterm delivery (2.21 [1.47-3.31]), and small-for-gestational-age infants (3.72 [2.32-5.98]). In France, the management of pregnancy in SCD follows national guidelines since 2015 and these patients are theoretically referred to centers trained in this disease but recent national data are lacking.